Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.
Statistics

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external video platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name Youtube
Purpose External media
Translational Gastrointestinal Oncology and Preclinical Models

Junior Clinical Cooperation Unit Translational Gastrointestinal Oncology and Preclinical Models

PD Dr. Johannes Betge

Patient derived organoids from a colorectal cancer patient, DNA (magenta), actin cytoskeleton (cyan), dead cells (yellow).
© dkfz.de

Carcinomas of the gastrointestinal tract are among the most common cancers. Despite recent advances in therapeutic options many cases cannot be cured, especially when the disease has spread and metastasized throughout the body. Our group therefore aims to develop novel, individualized therapies for patients with advanced gastrointestinal cancer and to analyze predictive markers, as well as mechanisms of resistance to therapies. For this, we are utilizing patient derived organoids (PDOs), up-to-date 3D cell culture models that we establish directly from our patients’ tumor or normal tissue biopsies. The organoids retain molecular characteristics of the original tissue and we can use them for functional analyses. We have established robotics-assisted high throughput-screening protocols that enable us to model drug response to hundreds of drugs simultaneously. We aim to translate these results of organoid-based drug screens back to bedside. Furthermore, we study tumor biology and the mechanisms of action and resistance of cancer drugs in tumors and organoids using high-throughput microscopy and single-cell sequencing. Thereby we aim to find markers for response and resistance that we further investigate in mechanistic studies. We are especially interested in the relevance of intracellular signaling pathways (most notably MAPK, IGF, PI3K/mTor) on tumor- and stem cell biology, drug response and development of drug resistance towards pharmacotherapies in colorectal cancer.

Prospectively, we aim to develop new treatments ex vivo in organoid models, most importantly using novel combinations of drugs, but also combining drugs and radiation therapy. Based on this, we will analyze their pertinent mechanisms of action and predictive markers. In a personalized approach using organoids and drug screening with clinically available anti-cancer drugs, we want to find individual therapeutic options for patients with advanced gastrointestinal cancer. We are currently testing this tailored approach in several clinical studies with our patients at the University Medical Center Mannheim (PROMISE studies).

Contact

PD Dr. Johannes Betge
Translational Gastrointestinal Oncology and Preclinical Models (B440)

Standort Heidelberg:
Im Neuenheimer Feld 580
Technologiepark 3
69120 Heidelberg

Standort Mannheim:
Universitätsklinikum Mannheim
II. Medizinische Klinik
Theodor-Kutzer-Ufer 1-3
68167 Mannheim

E-Mail: j.betge@dkfz.de

Selected Publications

  • Betge J, Rindtorff N, Sauer J, Rauscher B, Dingert C, Gaitantzi H, Herweck F, Srour-Mhanna K, Miersch T, Valentini E, Boonekamp KE, Hauber V, Gutting T, Frank L, Belle S, Gaiser T, Buchholz I, Jesenofsky R, Härtel N, Zhan T, Fischer B, Breitkopf-Heinlein K, Burgermeister E, Ebert MP, Boutros M. (2022) The drug-induced phenotypic landscape of colorectal cancer organoids. Nat Commun, 13:3135.
  • Riedesser J, Ebert MP, Betge J. (2022) Precision Medicine for Metastatic Colorectal Cancer in Clinical Practice. Therap Adv Med Oncol, 14:17588359211072703
  • Zhan T, Belle S, Valentini E, Herrmann S, Miersch T, Li M, Gaiser T, Boutros M, Ebert MP, Betge J. (2020) Cancer-Associated Mutations in Normal Colorectal Mucosa Adjacent to Sporadic Neoplasia. Clin Transl Gastroenterol, 11:e00212.
  • van Dijk E, Biesma HD, Cordes M, Smeets D, Neerincx M, Das S, Eijk PP, Murphy VS, Barat A, Bacon O, Prehn JHM, Betge J, Gaiser T, Fender B, Meijer GA, McNamara DA, Klinger R, Koopman M, Ebert MPA , Kay EW, Hennessey BT, Verheul HMW, Gallagher WM, O'Connor DP, Punt CJA, Loupakis F, Lambrechts D, Byrne AT, van Grieken NCT, Ylstra B. (2018) Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab. J Clin Oncol, 36:2052-60
to top
powered by webEdition CMS